Krystal Biotech, Inc. financial data

Symbol
KRYS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.71 K % +37.8%
Debt-to-equity 5.33 % -28%
Return On Equity 7.65 %
Return On Assets 7.27 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.6 M shares +10.7%
Common Stock, Shares, Outstanding 28.5 M shares +10.6%
Entity Public Float 2.8 B USD +100%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 28.3 M shares +10%
Weighted Average Number of Shares Outstanding, Diluted 29.3 M shares +13.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 45.3 M USD
Research and Development Expense 45.1 M USD -0.74%
General and Administrative Expense 93.9 M USD +67.1%
Operating Income (Loss) -67.6 M USD +53%
Net Income (Loss) Attributable to Parent 57.2 M USD
Earnings Per Share, Basic 2.19 USD/shares
Earnings Per Share, Diluted 2.18 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 359 M USD +155%
Cash, Cash Equivalents, and Short-term Investments 538 M USD +53.6%
Accounts Receivable, after Allowance for Credit Loss, Current 46.5 M USD
Inventory, Net 11 M USD
Assets, Current 602 M USD +69.4%
Property, Plant and Equipment, Net 160 M USD -1.88%
Operating Lease, Right-of-Use Asset 6.85 M USD -12.4%
Other Assets, Noncurrent 196 K USD -51.2%
Assets 853 M USD +60.4%
Accounts Payable, Current 5.36 M USD +30.4%
Liabilities, Current 47.6 M USD +35.7%
Operating Lease, Liability, Noncurrent 6.47 M USD -10.3%
Liabilities 54.1 M USD +27.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -299 K USD -94.2%
Retained Earnings (Accumulated Deficit) -269 M USD +17.5%
Stockholders' Equity Attributable to Parent 799 M USD +63.3%
Liabilities and Equity 853 M USD +60.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 15.9 M USD
Net Cash Provided by (Used in) Financing Activities 10.6 M USD +618%
Net Cash Provided by (Used in) Investing Activities -26 M USD -829%
Common Stock, Shares Authorized 80 M shares 0%
Common Stock, Shares, Issued 28.5 M shares +10.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 678 K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 359 M USD +155%
Deferred Tax Assets, Valuation Allowance 77 M USD -6.69%
Deferred Tax Assets, Gross 91.6 M USD +6.74%
Operating Lease, Liability 7.9 M USD -9.85%
Depreciation 5.34 M USD +63.1%
Payments to Acquire Property, Plant, and Equipment 1.26 M USD -76.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12.3 M USD
Lessee, Operating Lease, Liability, to be Paid 15.8 M USD -9.32%
Property, Plant and Equipment, Gross 175 M USD +2.44%
Operating Lease, Liability, Current 1.43 M USD -7.92%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.28 M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.28 M USD -17%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.88 M USD -8.78%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.3 M USD +1.8%
Deferred Tax Assets, Operating Loss Carryforwards 40 M USD -24%
Preferred Stock, Shares Issued 2.06 M shares 0%
Preferred Stock, Shares Authorized 20 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33 M USD +1.92%
Additional Paid in Capital 1.07 B USD +31%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 14.6 M USD +342%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%